drugset

drugset / Trial / NCT01930864

Metformin Plus Irinotecan for Refractory Colorectal Cancer

NCT01930864 ↗

Phase 2 Unknown 41 enrolled Barretos Cancer Hospital AC Camargo Cancer Center · collab University of Campinas, Brazil · collab

NaSingle-groupOpen-labelTreatment

Summary

MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.

Timeline

Start: 2015-09-01
Primary completion: 2020-12-01
Completion: 2020-12-01

Publications

Background Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	350 mg/m2	Intravenous
Subject	Metformin	Small molecule	2500 mg	—

Indications